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Abstract
Background: Sexual function in patients with breast cancer especially in younger patients is an important issue
from clinical and psychosocial perspectives. This study aimed to assess sexual function among Iranian breast cancer
patients.
Methods: This was a prospective study of sexual function in breast cancer patients attending the Cancer Institute
of Iran. Sexual function was assessed using the Female Sexual Function Index (FSFI) at two points in time: baseline
(pre-treatment) and after completion of cancer treatment at follow-up visits (post-treatment). Pre- and post-
treatment data were compared. In addition logistic regression analysis was performed to find out factors that
contributing to post-treatment sexual dysfunction.
Results: In all 277 breast cancer patients were approached. Of these, 231 patients (83%) were sexually active and
data for 216 patients (93.5% of sexually active patients) were available at pre-and post-treatment. Overall pre- and
post-treatment sexual dysfunction was found to be 52% and 84%, respectively indicating a significant deterioration
in sexual function among breast cancer patients. The results obtained from multiple logistic regression analysis
indicated that younger age [OR = 0.95, 95% CI = 0.93-0.98; P = 0.04], receiving endocrine therapy [OR = 3.34, 95%
CI = 1.37-7.91; P = 0.007] and poor sexual function at pre-treatment [OR = 12.3, 95% CI = 3.93-39.0; P < 0.0001]
were the most significant contributing factors to post-treatment sexual disorders.
Conclusion: A significant number of breast cancer patients experience deterioration in sexual function over time.
The findings from this study indicated that younger age, receiving endocrine therapy, and poor sexual function at
diagnosis were the most significant predicting factors for sexual disorders following treatment.
Background
Studying sexual function in women who lose their
breasts due to breast cancer and are sexually active is
vital issue from both clinical and psychosocial perspec-
tives [1]. A study on sexual quality of life in women
with newly diagnosed breast cancer indicated that about
60% of breast cancer patients reported disruption in
their sexual quality of life [2]. A recent publication on
sexual function after breast cancer studying 1,011
women reported that 70% of patients experienced sexual
function problems. The study also indicated that several
factors contributed to sexual function problems. Those
who received aromatase inhibitors were more likely to
experience more sexual function problems compared to
those who received tamoxifien but in both group body
image was the most contributing factor to sexual dys-
function [3]. These findings suggest that the impact of
breast cancer on sexuality is much more complex than
women simply losing their breasts or receiving different
treatment modalities.
Studies have shown that disrupted sexual functioning
or unsatisfactory sexual life was related to poorer quality
of life at younger age, treatment with chemotherapy,
total mastectomy, emotional distress consequent on an
unsatisfactory sexual life, and difficulties with partners
because of sexual relationships [4-8]. This latter factor
was further examined and recently a French study found
that ‘no sexual activity’ or ‘sexual dissatisfaction’ among
breast cancer patients were associated with the feeling
of emotional separation in the couple or of partner’s
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review of sexuality after breast cancer highlighted the
issue of ‘women’s intrapsychic’ experience of changes to
sexuality. They argued this experience includes a fear of
loss of fertility, negative body image, feelings of sexual
unattractiveness, loss of femininity, depression and anxi-
ety, as well as alterations to a sense of sexual self. Then
they concluded that sexuality in the context of breast
cancer could not be conceptualized the physical body
separately from women’s intrapsychic experience.
With any interpretations sexual functioning seems
important area that needs more attention, especially for
younger breast cancer survivors. It is argued that
younger survivors may need interventions that specifi-
cally target their needs related to menopausal symptoms
and problems with relationships, sexual functioning and
body image [11]. There is evidence that the quality of
sexual life in breast cancer survivors could be improved
with the sexual life reframing program focusing on the
physical, psychological, and relational aspects of sexual
health elements at couples rather than survivors only
and if delivered earlier and for a longer period [12].
No study so far has reported on prevalence of sexual
function among Iranian breast cancer patients. Breast
cancer patients in Iran are usually younger that their
western counterparts [13] and thus might report differ-
ent experiences. In addition women in Islamic countries
such as Iran usually have some reservations in talking
about and reporting sexual problems or seeking proces-
sional help [14]. The aim of this study was to elucidate
the issue and contribute to existing knowledge on the
topic and provide necessary information for implement-
ing possible future interventions in order to improve
quality of life in breast cancer patients.
Methods
Patients and data collection
This was a prospective study of sexual function among
breast cancer patients attending the Cancer Institute in
Tehran, Iran. Patients were included in the study if they
had confirmed diagnosis of breast cancer (any stages),
were married and sexually active. Patients were assessed
at two points in time: once before surgery and once
after surgery and completion of adjuvant treatment
(usually 3 months after chemotherapy or radiotherapy at
first follow-up visits). Demographic and clinical data
were collected at baseline and a sexual functioning ques-
tionnaire was completed for each patient at pre-and
post-treatment assessments.
Sexual function
Sexual function was assessed using the Female Sexual
Function Index (FSFI). The FSFI is a 19-itmes question-
naire that contains six subscales: sexual desire, arousal,
lubrication, orgasm, satisfaction and pain. It provides a
score for each subscale as well as a total score for the
whole questionnaire. The total score ranges from 2 to
36 with higher scores indicating a better sexual function
[15]. We used the Iranian version of the questionnaire.
The psychometric properties of the Iranian version are
well documented. The cut-off point for sexual disorder
for Iranian females was found to be 28 [16].
Statistical analysis
The analysis was restricted to patients for whom both
pre-and post-treatment data were available. In addition
to descriptive statistics, paired sample t-test was used to
compare sexual function before and after treatment.
Relative to cut-off point on the FSFI (less than 28 versus
28 or above), patients with and without sexual disorders
at post-treatment were indicated and the contribution of
demographic and clinical factors to sexual disorder was
investigated by performing both univariate and multiple
logistic regression analyses.
Ethics
The ethics committee of Tehran University of Medical
Sciences approved the study. All patients gave their
written informed consent.
Results
In all 277 patients with breast cancer were approached.
Of these 231 patients (83%) were sexually active and
were included in the study. Since 15 patients did not
complete the questionnaire at follow-up due to dislike,
the data for 216 patients (93.5% of sexually active
patients) were available for both pre-and post-treatment
evaluations. There were no significant score differences
on the FSFI between those who did not participate at
follow-up assessment and the rest of patients (n = 216)
at baseline (the results are not show and is available
from the corresponding authors). The characteristics of
patients and the mean duration follow-up (time interval
between pre- and post-treatment evaluations) are pre-
sented in Table 1.
The mean score of patients on the FSFI at pre-and
post-treatment was 26.6 (SD = 4.26) and 22.1 (SD =
5.89) respectively indicating a significant deterioration in
sexual function among the study sample at post-treat-
ment (P < 0.0001). At post-treatment assessment scores
for sexual desire and lubrication showed greater
decrease compared to other domains. The findings indi-
cated that 52% of breast cancer patients at pre-treat-
ment and 84% at post-treatment were suffering from
poor sexual function. The results are shown in Table 2.
The results obtained from multiple logistic regression
analysis indicated that the most significant contributing
factors to sexual disorder at post-treatment were
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Page 2 of 6Table 1 The characteristics of the study sample (n = 216)
No. %
Demographic status
Age
≤ 40
41-45 45 20.8
46-50 51 23.6
51-55 47 21.8
56 ≥ 32 14.8
Mean (SD) 44.3 (8.6)
Education
Illiterate
Primary 111 51.4
Secondary 61 28.2
Higher 16 7.4
Employment
Housewife 85.6
Employed 31 14.4
Clinical status
Disease stage
I
II 91 42.1
III 39 18.1
Unknown 54 25.0
Surgery
Conservative
Mastectomy 156 72.2
Chemotherapy
Yes 200 92.6
No 16 7.4
Radiotherapy
Yes 187 86.6
No 29 13.4
Endocrine therapy
Yes 162 75.0
No 54 25.0
Sexual status
Age at marriage
Mean (SD) 19.1 (4.2) -
Age at first intercourse
Mean (SD) 19.3 (4.2)
Intercourse per week
1-2 times 196 90.7
3-4 times 17 7.9
> 4 times 3 1.4
Time interval between pre- and post-treatment evaluations (months) Mean (SD) 9.1 (1.06)
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Page 3 of 6younger age [OR = 0.95, 95% CI = 0.93-0.98; P = 0.04],
receiving endocrine treatment [OR = 3.34, 95% CI =
1.38-8.06; P = 0.007], and poorer sexual dysfunction at
pre-treatment [OR = 12.3, 95% CI = 3.93-39.0; P <
0.0001]. Other variables in the model did not show any
significant results. Table 3 presents the findings.
Discussion
T h ef i n d i n g sf r o mt h i sp r o s p ective study indicated that
the prevalence of sexual dysfunction among Iranian
breast cancer patients was relatively high. The findings
also indicated that younger age, receiving endocrine
therapy and pre-treatment sexual dysfunction were inde-
pendent and significant contributing variables to post-
treatment sexual disorders. It is well documented that
endocrine effects of adjuvant therapy, especially che-
motherapy, in younger survivors causes premature
menopause that is associated with poorer quality of life,
decreased sexual functioning, menopausal symptom dis-
tress, and psychosocial distress related to infertility [17],
although it is believed that as a whole adjuvant endo-
crine therapy or radiation therapy for early stage breast
cancer do not causes premature menopause. As noted
by Cella and Fallowfield [18], recognition and manage-
ment of treatment-related side-effects for breast cancer
patients receiving adjuvant endocrine therapy is an
important issue since such side-effects negatively affect
sexual functioning, health-related quality of life and
adherence to therapy. They argue that adverse events
across all adjuvant endocrine trials regardless of the
treatment, vasomotor symptoms such as hot flushes are
the most common side effects. Other frequently
reported side-effects such as vaginal discharge, vaginal
dryness, dyspareunia, and arthralgia vary in prevalence
between tamoxifen and aromatase inhibitors [18].
Although there were significant decreases in all mea-
sures at post-treatment assessment compared to pre-
treatment evaluation, greater decrease was observed for
sexual desire (3.8 vs. 2.8) and lubrication (5.3 vs. 4.3).
Perhaps these are very important aspect of sexual life
for women and should receive further attention when
studying sexual issues in breast cancer patients. It has
been shown that sexual desire and lubrication are two
important affecting factors in breast cancer survivors
after mastectomy [19]. In addition a study from Switzer-
land using the FSFI found that the only predictor for
desire was quality of relationship while chemotherapy
was predictive for problems with arousal, lubrication,
orgasm, and sexual pain. The authors concluded that
sexual dysfunction after breast cancer is common and
thus women should be informed properly at an early
stage of treatment. They suggested that specific inter-
ventions have to be offered considering person-related
preexisting factors and couples at risk should be sup-
ported in the transition to a new sexual life after breast
cancer [20].
In univariate analysis chemotherapy was found to have
a significant association with post-treatment sexual dis-
order. However, in multiple logistic regression analysis
this significant association was disappeared. One expla-
nation for such observation might be due to the fact
that we included endocrine therapy as an independent
factor in the regression analysis and thus the hormonal
side effects of endocrine therapy masked the hormonal
side effects of chemotherapy in the final model.
Although we adjusted the regression model for the time
interval between pre-and post-treatment evaluations,
another possibility for such results might be due to the
fact that there were different time point for evaluations
between the patients who received hormonal therapy
and chemotherapy. In fact many patients received the
chemotherapy and hormonal therapy together with
sequential process.
Pretreatment sexual disorder appeared as important
predicting factor for post-treatment sexual dysfunction.
In fact many women indicated that they were suffering
from sexual disorders even before diagnosis of breast
cancer. This is why some investigators argued that the
negative effects of cancer and its management on sexual
function and satisfaction can be somewhat mitigated by
understanding pre-diagnosis sexual functioning level
[21]. A study indicated that two main issues affect breast
Table 2 Pre- and post-treatment sexual functioning in
breast cancer patients as measured by the Female Sexual
Function Index-FSFI (higher scores indicate a better
function, n = 216)
Pre-
treatment
Post-
treatment
Mean (SD) Mean (SD) Effect
size
P*
FSFI domains
Sexual desire 3.8 (0.97) 2.8 (1.13) 0.95 < 0.001
Arousal 4.1(1.25) 3.2 (1.45) 0.66 < 0.001
Lubrication 5.3(1.01) 4.3 (1.48) 0.79 < 0.001
Orgasm 4.8(1.17) 4.0 (1.47) 0.60 < 0.001
Satisfaction 3.3(1.47) 3.0 (1.26) 0.22 < 0.001
Pain 5.2(1.19) 4.5 (1.63) 0.49 < 0.001
Total FSFI
score
26.6 (4.26) 22.1 (5.89) 0.87 < 0.001
Range 7.2-34.2 2.8-32.9 - -
Sexual
disorder†
Number (%) Number (%) <
0.0001¶
No 103 (48) 34 (16)
Yes 113 (52) 182 (84) - -
* Derived from paired t-test.
† According to cut-off point score for Iranian females [16].
¶ Derived from Chi-square test.
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sonality and psychological factors. The study found that
clinical factors did not predict quality of sexual life, sex-
ual functioning and sexual enjoyment [22]. However,
studies have shown that compared with pre-treatment
levels considerably more women report moderate or
severe problems with sexual interest and sexual activity
over time. It was suggested that upper limb dysfunction,
such as that caused by lymphedema, might be a signifi-
cant factor that interfere with sexual functioning in
breast cancer patients [23]. A recent publication
reported that the presence of mood disorder, but not
fatigue, demographic, or treatment variables, indepen-
dently predicted worse overall sexual satisfaction. The
study concluded that sexual dysfunction is common
after breast cancer therapy and impacts quality of life
and interventions should include identification and
treatment of concomitant mood disorder [24]. A sys-
tematic review of the literature on interventions for sex-
ual problems following treatment for breast cancer
indicated that tentative findings of the studies under
review suggest that the most effective interventions are
couple-based psycho-educational interventions that
include an element of sexual therapy [25]. However, as
discussed by Krychman and Katz [26] sexual dysfunction
during or following cancer therapy is a very complex
disorder. They suggest that care and consultation
between the survivor, her partner, the oncologists, and
primary care practitioner should be aimed at discussing
individualized treatment plans that minimize risk and
maximize sexual wellness.
This study has some strengths including a prospective
design, the use of a validated measure of sexual function
and the fact that we are reporting from a diverse popu-
lation where cultural and religious issues play important
role in women’s sexual life. For instance desire for sex
by women (asking or showing interest in sex) is per-
ceived negatively and always men must initiate; or the
husband’s preferences and satisfaction are more impor-
tant than the wife’s satisfaction and thus if husbands
were satisfied, women tend to show that they are satis-
f i e d ,t o o[ 2 7 ] .H o w e v e r ,t h ep r e s e n ts t u d ys u f f e r sf r o m
Table 3 The results obtained from logistic regression indicating factors predicting sexual dysfunction at post
treatment in breast cancer patients (n = 216)
OR (95% CI)* P OR (95% CI)** P
Age 0.96 (0.94-0.99) 0.05 0.95 (0.93-0.98) 0.04
Education
Illiterate 1.0 (ref.) 1.0 (ref.)
Primary 1.61 (0.56-4.61) 0.36 1.32 (0.36-4.80) 0.66
Secondary/higher 1.47 (0.49-4.40) 0.48 1.28 (0.32-5.01) 0.72
Employment
Housewife 1.0 (ref.) 1.0 (ref.)
Employed 1.03 (0.36-2.91) 0.94 1.55 (0.38-6.27) 0.53
Surgery
Conservative 1.0 (ref.) 1.0 (ref.)
Mastectomy 1.30 (0.55-3.05) 0.54 1.07 (0.36-3.22) 0.89
Chemotherapy
No 1.0 (ref. 1.0 (ref.)
Yes 1.88 (1.10-6.24) 0.03 1.34 (0.25-7.31) 0.73
Radiotherapy
No 1.0 (ref.) 1.0 (ref.)
Yes 1.88 (0.73-4.84) 0.18 2.30 (0.57-9.31) 0.24
Endocrine therapy
No 1.0 (ref.) 1.0 (ref.)
Yes 3.36 (1.57-7.22) 0.002 3.34 (1.38-8.06) 0.007
Pre-treatment sexual dysfunction
No 1.0 (ref.) 1.0 (ref.)
Yes 11.1 (3.78-33.1) < 0.0001 12.3 (3.93-39.0) < 0.0001
Time interval between pre-and post-treatment evaluations (months) - - 1.10 (0.33-3.63) 0.21
* Obtained from univariate logistic regression analysis
** Obtained from multiple logistic regression analysis (adjusted odds ratio)
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pausal status or detailed data on the relative use of
tamoxifien versus aromatase inhibitors by patients. This
information might be necessary for regression analysis
in order to have a better interpretation of the results.
Conclusion
Breast cancer patients might show deterioration in sex-
ual function over time. The findings from this study
indicated that younger age, receiving endocrine therapy,
and poor sexual function at diagnosis were the most sig-
nificant predicting factors for sexual disorders in Iranian
breast cancer patients following treatment.
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